Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375674 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 674
- Enrollment target
NCT00375674 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 674 participants.
The verdict
NCT00375674, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 674 participants
- Enrollment target
Study Summary
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
Interventions
- OTHER Placebo
- DRUG Sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2007-08-01 |
| Est. Completion | 2017-09-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375674
The ClinicalTrials.gov registry entry for NCT00375674 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 674 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00375674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375674 about?
NCT00375674 is a clinical study titled "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer". To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
What is the current status of trial NCT00375674?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 674 participants. The study started on 2007-08-01. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT00375674?
The interventions under investigation include: Placebo (OTHER), Sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00375674?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.